SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Biotechs > Peregrine Pharmaceuticals (PPHM)

I don't know about the rest of you,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
pphmtoolong Member Profile
 
Followed By 26
Posts 3,616
Boards Moderated 0
Alias Born 07/17/06
160x600 placeholder
Amended Statement of Beneficial Ownership (sc 13d/a) "Edgar (US Regulatory)" - 5/19/2017 4:36:33 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/28/2017 7:00:04 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/28/2017 6:58:33 PM
Statement of Beneficial Ownership (sc 13d) "Edgar (US Regulatory)" - 4/17/2017 2:28:10 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 4/12/2017 4:56:55 PM
Peregrine Pharmaceuticals Highlights Clinical Data Presentation at AACR 2017 Annual Meeting Supporting Potential of Bavituxim... "GlobeNewswire Inc." - 4/4/2017 8:05:00 AM
Peregrine Pharmaceuticals Announces Presentation of Preclinical Study Results Highlighting Potential of PS-Targeting Antibodi... "GlobeNewswire Inc." - 4/3/2017 8:05:00 AM
Peregrine Pharmaceuticals Announces Five Abstracts Accepted for Presentation at AACR 2017 Annual Meeting "GlobeNewswire Inc." - 3/23/2017 7:05:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 3/13/2017 4:48:53 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 3/13/2017 4:35:23 PM
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent Developments "GlobeNewswire Inc." - 3/13/2017 4:05:00 PM
Amended Statement of Beneficial Ownership (sc 13d/a) "Edgar (US Regulatory)" - 3/10/2017 4:50:07 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 3/9/2017 4:27:02 PM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 3/9/2017 4:05:00 PM
Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2017 After Market Close on March 13, 2017 "GlobeNewswire Inc." - 3/6/2017 8:05:00 AM
Statement of Beneficial Ownership (sc 13d) "Edgar (US Regulatory)" - 3/2/2017 5:00:58 PM
Avid Bioservices to Participate at Upcoming Life Sciences Industry Conferences "GlobeNewswire Inc." - 2/22/2017 8:05:00 AM
Recent Publication Highlights Proof-of-Concept Data Supporting the Diagnostic Potential of Phosphatidylserine-Positive Exosom... "GlobeNewswire Inc." - 2/9/2017 8:05:00 AM
pphmtoolong   Tuesday, 04/24/12 10:44:52 AM
Re: None
Post # of 297901 
I don't know about the rest of you, but I bought this stock based on Thorpe's approved patents and the early Bavi clinical studies.

It seems that Peregrine management and BOD have done everything reasonable to forward the Bavi agenda given the limited financial resources available. Running the trials overseas in Georgia and India could not have been easy, but they did it and got promising results. As in many other cases Bavi may not pan out in later stage trials. I don't blame management for trying with Bavi, and I don't blame management for the perversity of Mother Nature. I could blame them for excessive optimism, but the science seemed sound to them just as it seemed sound to us.

I don't like that managment has diluted the heck out of our stock, but I really don't buy any of the alternative financing plans I've seen presented here. I am a retired CPA; so I have some confidence assessment on this point.

If Bavi finally hits it out of the park with second line NSCLC, there is still a chance for us to make money. Otherwise, this has been a very expensive lesson in wishful thinking on biotechs. I blame only myself if Peregrine flops. I never should have thrown so much money into such a crap shoot.

Paul


SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist